Detalles de la búsqueda
1.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet
; 397(10275): 671-681, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33545094
2.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Lancet
; 396(10255): 887-897, 2020 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32896291
3.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Front Immunol
; 14: 1228461, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37600800
4.
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.
Front Immunol
; 13: 1023164, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36466896
5.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
Lancet Reg Health Eur
; 11: 100241, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34746910
Resultados
1 -
5
de 5
1
Próxima >
>>